Evaluating only BIND Biosciences’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
Founded in Cambridge, MA, by MIT professors Robert Langer and Omid Farokhzad to develop targeted nanoparticles.
FUNDING
Raised $60M in NASDAQ IPO to advance BIND-014 nanoparticle docetaxel into Phase 2 oncology trials.
PRODUCT LAUNCH
Phase 2 data in prostate cancer showed BIND-014 offered no meaningful improvement over standard docetaxel therapy.
BANKRUPTCY
BIND filed Chapter 7 bankruptcy and sold all assets for approximately $8M after failing to raise new capital.
Full Analysis
Free · no account needed
Documented cause
BIND Biosciences developed Accurins, targeted polymeric nanoparticles for cancer drug delivery. Its lead asset BIND-014 (docetaxel nanoparticle) failed to show meaningful benefit over standard docetaxel in Phase 2 prostate cancer trials announced in late 2015. Having raised $60M in its 2013 IPO and $157M total, the company could not raise additional capital and filed for Chapter 7 bankruptcy in August 2016, selling assets for $8M.
Lesson
“Nanoparticle drug delivery must demonstrate clear superiority over standard of care, not just biological novelty.”